A5025650421- Breast Cancer Treatment Studies
- Breast Lesions and Carcinomas
- Breast Implant and Reconstruction
- Cancer Treatment and Pharmacology
- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Immune cells in cancer
- Cancer and Skin Lesions
- Nonmelanoma Skin Cancer Studies
- Research in Social Sciences
- MRI in cancer diagnosis
- Health Systems, Economic Evaluations, Quality of Life
- Thyroid and Parathyroid Surgery
- Hemostasis and retained surgical items
- Colorectal Cancer Screening and Detection
- Advanced Radiotherapy Techniques
- HER2/EGFR in Cancer Research
- Immune Cell Function and Interaction
- Global Cancer Incidence and Screening
University of Helsinki
2017-2025
Helsinki University Hospital
2017-2025
Finnish Cancer Registry
2025
There is no consensus on axillary management after neoadjuvant therapy (NAT) in patients with clinically node-positive (cN+) breast cancer. To investigate current clinical practice, an international survey was conducted among surgeons and radiation oncologists. The aim of the first part to provide a snapshot discrepancies regarding surgery this context.The European Breast Cancer Research Association Surgical Trialists (EUBREAST) developed web-based containing 39 questions describing...
Combining cytotoxic chemotherapy or novel anticancer drugs with T-cell modulators holds great promise in treating advanced cancers. However, the response varies depending on tumor immune microenvironment (TIME). Therefore, there is a clear need for pharmacologically tractable models of TIME to dissect its influence mono- and combination treatment at individual level.
Tumor-resident immune cells play a crucial role in eliciting anti-tumor immunity and immunomodulatory drug responses, yet these functions have been difficult to study without tractable models of the tumor microenvironment (TIME). Patient-derived ex vivo contain authentic resident therefore, could provide new mechanistic insights into how TIME responds or cell-directed therapies. Here, we assessed reproducibility robustness responses across two different breast cancer one renal cell...
Within Finland's breast cancer screening program, all women aged 50-69 are invited to biennial screening. Current European guidelines recommend in ages 45-49 and 70-74 conditional upon, inter alia, demonstrated context-specific cost-effectiveness. This study aims determine the cost-effectiveness of expanding target population 45 and/or 74, compared current national strategy, Finnish setting. Screening strategies' costs quality-adjusted life years (QALY), aggregated over a lifetime horizon...
This study aims to compare the feasibility of VAE and BLES in treatment intraductal papillomas.
Abstract Background The aim of this study was to determine preoperative factors and tumour characteristics related a high nodal burden in patients with clinically node-positive breast cancer. These findings were used construct predictive tool evaluate the patient-specific risk having more than two axillary lymph node metastases. Methods Altogether, 507 consecutive cancer metastasis diagnosed by ultrasound-guided needle biopsy reviewed. underwent surgery dissection at Helsinki University...
Abstract Background The optimal surgical staging procedure of the axilla in patients who convert from a clinically positive (cN+) to negative node status (ycN0) through neoadjuvant chemotherapy is still controversial. Widely diverse techniques such as full Axillary Lymph Node Dissection (ALND), Targeted (TAD), Biopsy (TLNB) and Sentinel (SLNB) alone are given preference different international guidelines. So far, no comparative data on oncological outcome or morbidity procedures available....
ABSTRACT Tumor-resident immune cells play a crucial role in eliciting anti-tumor immunity and immunomodulatory drug responses, yet these functions have been difficult to study without tractable models of tumor microenvironment (TIME). Patient-derived ex vivo contain authentic resident therefore, could provide new mechanistic insights into how TIME responds or cell-directed therapies. Here, we assessed the reproducibility robustness responses across two different breast cancer one renal cell...
ABSTRACT Combining cytotoxic chemotherapy or novel anticancer drugs with T-cell modulators holds great promise in treating advanced cancers. However, the response varies depending on tumor immune microenvironment (TIME). Therefore, there is a clear need for pharmacologically tractable models of TIME to dissect its influence mono- and combination treatment at individual level. Here we establish Patient-Derived Explant Culture (PDEC) model breast cancer, which retains contexture primary tumor,...
Abstract Background The optimal surgical staging procedure of the axilla in patients who convert from a clinically positive (cN+) to negative node status (ycN0) through neoadjuvant chemotherapy is still controversial. Widely diverse techniques such as full Axillary Lymph Node Dissection (ALND), Targeted (TAD), Biopsy (TLNB) and Sentinel alone (SLNB) are given preference different international guidelines. So far, no comparative data on oncological outcome or morbidity procedures available....
Einleitung Die systematische axilläre Lymphknotendissektion (ALND) stellte über sehr lange Zeit den Standard in der operativen Therapie des Mammakarzinoms dar. In letzten zwei Jahrzehnten hat eine stufenweise Deeskalation Axillachirurgie stattgefunden mit dem Ziel einer Morbiditätsreduktion ohne Kompromittierung onkologischen Sicherheit zu riskieren. Bei Patientinnen, die nach neoadjuvanten Chemotherapie vom cN+ zum cN0 Stadium konvertieren, wird Methode Wahl im axillären Staging allerdings...
Background The optimal surgical axillary staging for breast cancer patients converting from cN+ to ycN0 after neoadjuvant chemotherapy (NACT) is controversial. ongoing AXSANA study aims assess whether de-escalation of surgery possible in these without a loss oncologic safety and it can improve quality life. current status recruitment management the included so far are presented.